TOT BIOPHARM International Company Limited (1875.HK)
HKD 1.65
(0.0%)
HKD 1.65
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 780.62 Million | 442.17 Million | 76.32 Million | 22.49 Million | 45.3 Million | 39.21 Million |
| Cost of Revenue | 206.64 Million | 71.56 Million | 48.85 Million | 6.96 Million | 11.31 Million | 5.98 Million |
| Gross Profit | 573.98 Million | 370.61 Million | 27.47 Million | 15.53 Million | 33.99 Million | 33.23 Million |
| Operating Expenses | 607.04 Million | 409.44 Million | 282.92 Million | 305.26 Million | 305.48 Million | 269.84 Million |
| Selling, General and Administrative Expenses | 509.32 Million | 266.54 Million | 79.18 Million | 72.8 Million | 126.63 Million | 70.14 Million |
| Research and Development Expenses | 103.89 Million | 151.16 Million | 214.69 Million | 235.19 Million | 191.07 Million | 188.65 Million |
| Other Expenses | -6.17 Million | 500 Thousand | 262 Thousand | 394 Thousand | -12.22 Million | 11.05 Million |
| Cost and Expenses | 813.68 Million | 481.01 Million | 331.77 Million | 312.22 Million | 316.8 Million | 275.82 Million |
| Operating Income | -33.06 Million | -39.07 Million | -259.7 Million | -288.67 Million | -271.49 Million | -237.17 Million |
| Interest Expense | 5.17 Million | 6.6 Million | 2.46 Million | 1.7 Million | 2.29 Million | 2.4 Million |
| Income Tax Expense | 1000.00 | -2.59 Million | 2.46 Million | 4.28 Million | 31.87 Million | -29.25 Million |
| Earnings before Tax | -37.75 Million | -50.04 Million | -261.21 Million | -288.49 Million | -299.3 Million | -268.26 Million |
| Net Income | -37.75 Million | -49.91 Million | -261.21 Million | -288.49 Million | -331.17 Million | -268.26 Million |
| Earnings Per Share Basic | -0.05 | -0.08 | -0.46 | -0.51 | -0.99 | -0.47 |
| Earnings Per Share Diluted | -0.05 | -0.08 | -0.46 | -0.51 | -0.99 | -0.47 |
| Weighted Average Shares Outstanding | 725.2 Million | 639.3 Million | 573.36 Million | 570.33 Million | 335.65 Million | 570 Million |
| Weighted Average Shares Outstanding (Diluted) | 725.19 Million | 639.3 Million | 573.36 Million | 570.33 Million | 335.65 Million | 570 Million |
| Gross Margin | 0.74 | 0.84 | 0.36 | 0.69 | 0.75 | 0.85 |
| EBIT Margin | 0.01 | -0.01 | -2.87 | -11.34 | -5.30 | -5.65 |
| Profit Margin | -0.05 | -0.11 | -3.42 | -12.83 | -7.31 | -6.84 |
| EBITDA | 10.44 Million | -5.4 Million | -224.51 Million | -254.71 Million | -240.07 Million | -221.41 Million |
| Earnings Before Tax Margin | -0.04 | -0.09 | -3.40 | -12.84 | -5.99 | -6.05 |
| Breakdown | 2024 Q2 | 2023 Q4 | 2023 FY | 2023 Q2 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Revenue | 520.6 Million | 452.56 Million | 780.62 Million | 328.06 Million | 442.17 Million | 260.15 Million |
| Cost of Revenue | 143.69 Million | 128.58 Million | 206.64 Million | 78.06 Million | 71.56 Million | 48.08 Million |
| Gross Profit | 376.9 Million | 323.98 Million | 573.98 Million | 250 Million | 370.61 Million | 212.07 Million |
| Operating Expenses | 343.64 Million | 342.46 Million | 595.43 Million | 264.18 Million | 409.44 Million | 245.06 Million |
| Selling, General and Administrative Expenses | 308.58 Million | 280.53 Million | - | 228.48 Million | - | 171.34 Million |
| Research and Development Expenses | 46.05 Million | 53.92 Million | - | 49.96 Million | - | 80.9 Million |
| Other Expenses | -10.99 Million | 8.01 Million | 90 Thousand | - | 500 Thousand | - |
| Cost and Expenses | 487.34 Million | 471.05 Million | 802.07 Million | 342.24 Million | 481.01 Million | 293.14 Million |
| Operating Income | 33.25 Million | -18.48 Million | -33.06 Million | -14.57 Million | -39.07 Million | -31.98 Million |
| Interest Expense | - | - | 5.17 Million | 2.55 Million | 6.6 Million | 3.57 Million |
| Income Tax Expense | - | 12.02 Million | 1000.00 | 1000.00 | -2.59 Million | 819.11 Thousand |
| Earnings before Tax | 31.55 Million | -22.59 Million | -37.75 Million | -15.16 Million | -50.04 Million | -34.32 Million |
| Net Income | 31.55 Million | -22.59 Million | -37.75 Million | -15.16 Million | -49.91 Million | -34.19 Million |
| Earnings Per Share Basic | 0.04 | -0.03 | - | -0.02 | - | -0.05 |
| Earnings Per Share Diluted | 0.04 | -0.03 | - | -0.02 | - | -0.05 |
| Weighted Average Shares Outstanding | 725.21 Million | 725.21 Million | 725.2 Million | 725.22 Million | 639.3 Million | 703.42 Million |
| Weighted Average Shares Outstanding (Diluted) | 725.19 Million | 725.19 Million | 725.19 Million | 725.19 Million | 639.3 Million | 703.41 Million |
| Gross Margin | 0.72 | 0.72 | 0.74 | 0.76 | 0.84 | 0.82 |
| EBIT Margin | 0.12 | 0.03 | - | 0.01 | - | -0.06 |
| Profit Margin | 0.06 | -0.05 | -0.05 | -0.05 | -0.11 | -0.13 |
| EBITDA | 61.76 Million | 15.75 Million | - | 2 Million | - | -14.49 Million |
| Earnings Before Tax Margin | 0.06 | -0.04 | -0.04 | -0.04 | -0.09 | -0.12 |
EBTC
HUBN
BZWR
002229
DEXP4
SWTQ